

Expanded recall announced for ibuprofen oral suspension drops

January 31 2019



(HealthDay)—An expanded recall of ibuprofen oral suspension drops

that may contain higher-than-specified levels of ibuprofen that could harm infants' kidneys has been announced by Tris Pharma, Inc.

The original recall last November was for three lots of ibuprofen oral suspension drops, USP, 50 mg per 1.25 mL. The expanded recall adds three more lots. The products—packaged in 0.5-oz and 1-oz bottles—were sold under different names at various pharmacies: Equate at Wal-Mart, CVS Health at CVS, and Family Wellness at Family Dollar.

"Infants already susceptible to the adverse effects of ibuprofen may be at a slightly [higher risk](#) if they receive medication from an impacted bottle. There is a remote probability that infants, who may be more susceptible to a higher potency level of drug, may be more vulnerable to permanent nonsteroidal anti-inflammatory drug-associated (kidney) injury," according to a Tris Pharma news release. "Some units from these six lots have been found to contain Ibuprofen as high as 10 percent above the specified limit. Studies have shown that [safety issues](#) or toxicity is generally accepted to be a concern in infants at doses in excess of 700 percent of the recommended dose. To date, no serious adverse events have been reported related to this recall."

For more information about the recall, [health care providers](#) and consumers can call Tris Pharma at 732-940-0358.

More information: [More Information](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: Expanded recall announced for ibuprofen oral suspension drops (2019, January 31) retrieved 24 April 2024 from <https://medicalxpress.com/news/2019-01-recall-ibuprofen-oral-suspension.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.